NASDAQ:RGLS - Regulus Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.28 -0.01 (-3.45 %)
(As of 07/23/2018 02:00 AM ET)
Previous Close$0.28
Today's Range$0.2776 - $0.3066
52-Week Range$0.27 - $1.52
Volume1.26 million shs
Average Volume1.12 million shs
Market Capitalization$29.21 million
P/E Ratio-0.29
Dividend YieldN/A
Beta1.76
Regulus Therapeutics logoRegulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

Receive RGLS News and Ratings via Email

Sign-up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:RGLS
CUSIP75915K10
Phone858-202-6300

Debt

Debt-to-Equity RatioN/A
Current Ratio1.66
Quick Ratio1.66

Price-To-Earnings

Trailing P/E Ratio-0.29
Forward P/E Ratio-0.50
P/E GrowthN/A

Sales & Book Value

Annual Sales$70,000.00
Price / Sales417.28
Cash FlowN/A
Price / CashN/A
Book Value$0.34 per share
Price / Book0.82

Profitability

EPS (Most Recent Fiscal Year)($0.96)
Net Income$-71,900,000.00
Net Margins-94,318.05%
Return on Equity-214.48%
Return on Assets-92.85%

Miscellaneous

Employees63
Outstanding Shares104,320,000
Market Cap$29.21

Regulus Therapeutics (NASDAQ:RGLS) Frequently Asked Questions

What is Regulus Therapeutics' stock symbol?

Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc (NASDAQ:RGLS) issued its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.15). The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. Regulus Therapeutics had a negative net margin of 94,318.05% and a negative return on equity of 214.48%. View Regulus Therapeutics' Earnings History.

When is Regulus Therapeutics' next earnings date?

Regulus Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Regulus Therapeutics.

What price target have analysts set for RGLS?

7 brokers have issued twelve-month price objectives for Regulus Therapeutics' stock. Their forecasts range from $0.50 to $6.00. On average, they anticipate Regulus Therapeutics' share price to reach $2.10 in the next year. This suggests a possible upside of 650.0% from the stock's current price. View Analyst Ratings for Regulus Therapeutics.

What is the consensus analysts' recommendation for Regulus Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last year. There are currently 7 hold ratings for the stock, resulting in a consensus recommendation of "Hold."

Who are some of Regulus Therapeutics' key competitors?

Who are Regulus Therapeutics' key executives?

Regulus Therapeutics' management team includes the folowing people:
  • Mr. Joseph P. Hagan, Pres, CEO & Director (Age 49)
  • Mr. Daniel R. Chevallard, Chief Financial Officer (Age 38)
  • Dr. Timothy Michael Wright, Chief R&D Officer (Age 62)
  • Dr. Mark Deeg, Chief Medical Officer (Age 58)
  • Ms. Allison Wey, VP of Investor Relations & Corp. Communications

Has Regulus Therapeutics been receiving favorable news coverage?

Press coverage about RGLS stock has trended somewhat positive this week, according to Accern. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Regulus Therapeutics earned a daily sentiment score of 0.07 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 47.10 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Regulus Therapeutics?

Shares of RGLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regulus Therapeutics' stock price today?

One share of RGLS stock can currently be purchased for approximately $0.28.

How big of a company is Regulus Therapeutics?

Regulus Therapeutics has a market capitalization of $29.21 million and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-71,900,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. Regulus Therapeutics employs 63 workers across the globe.

How can I contact Regulus Therapeutics?

Regulus Therapeutics' mailing address is 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-202-6300 or via email at [email protected]


MarketBeat Community Rating for Regulus Therapeutics (NASDAQ RGLS)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  363 (Vote Outperform)
Underperform Votes:  181 (Vote Underperform)
Total Votes:  544
MarketBeat's community ratings are surveys of what our community members think about Regulus Therapeutics and other stocks. Vote "Outperform" if you believe RGLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.